Abstract
P19-55 LB. Effective control of a pathogenic SIVmac239 challenge by a novel heterologous mucosal prime and intramuscular boost vaccine strategy
Highlights
Open AccessEffective control of a pathogenic SIVmac239 challenge by a novel heterologous mucosal prime and intramuscular boost vaccine strategy
The failure of a recombinant adenovirus serotype 5 vector-based vaccine for HIV-1 in a phase 2b efficacy study in humans calls for efforts to develop novel vaccination strategies
We developed a recombinant replicationcompetent modified vaccinia Tiantan (MVTT), namely rMVTTSIVgpe, as a mucosal vaccine expressing SIVmac Gag, Pol and Env
Summary
Effective control of a pathogenic SIVmac239 challenge by a novel heterologous mucosal prime and intramuscular boost vaccine strategy. Address: 1AIDS Institute, The University of Hong Kong LKS Faculty of Medicine, Hong Kong, PR China, 2Guangzhou Institute of Biomedicine and Health, Chinese Academy of Scie, Guanzhou, Guangdong, PR China and 3Comprehensive AIDS Research Center, Tsinghua University; AIDS Research, Beijing, PR China. Published: 22 October 2009 Retrovirology 2009, 6(Suppl 3):P419 doi:10.1186/1742-4690-6-S3-P419. AIDS Vaccine 2009 Anna Laura Ross Meeting abstracts - A single PDF containing all abstracts in this Supplement is available here. http://www.biomedcentral.com/content/pdf/1471-2105-10-S12-info.pdf
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
